Wells Fargo has begun research coverage of Progyny, a fertility benefits provider, assigning it an overweight rating and a price target of $37, which implies a 45% upside from its recent closing price.
Analyst Stan Berenshteyn highlighted that Progyny is well-positioned at the intersection of demographic trends, corporate wellness initiatives, and healthcare innovation, showcasing strong success rates and return on investment. The company’s strategic partnerships and global expansion efforts are expected to enhance its market share and client spending.
Additionally, Progyny has introduced Progyny Select, a new plan offering fully-insured, supplemental fertility and family-building services, further strengthening its market proposition. This positive outlook aligns with broader market sentiment, as 9 out of 11 analysts currently rate Progyny as a buy or strong buy, according to LSEG data.
Over the past year, Progyny's shares have appreciated approximately 13%, reflecting growing investor confidence in its business model